The partnership will capitalize on the combined capabilities of the two organizations
The appointment is effective from May 01, 2023 for five years
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
A pharma industry veteran with over three decades of experience in domestic as well as international markets
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Subscribe To Our Newsletter & Stay Updated